{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:34:13Z","timestamp":1791988453007,"version":"4.4.0"},"reference-count":12,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This was a subgroup analysis of age group, dexamethasone use, and very highly emetogenic chemotherapy (VHEC) use from a randomised, multicentre, double\u2010blind, Phase 3 study of oral aprepitant in paediatric subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Subjects aged 6 months to 17 years scheduled to receive chemotherapeutic agents associated with at least moderate risk for emesis were randomly assigned to receive either aprepitant plus ondansetron (aprepitant regimen) or placebo plus ondansetron (control regimen); both could be administered with or without dexamethasone. This secondary analysis evaluated subjects stratified by pre\u2010specified age groups, dexamethasone use, and VHEC use. The primary endpoint of this analysis was the proportion of subjects who experienced complete response (CR) during the delayed phase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CR rates in the delayed phase were numerically higher with the aprepitant than the control regimen across all age categories, and reached significance for subjects aged 12\u201317 years (51%\u00a0vs. 10%; <jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.0001). In subjects receiving dexamethasone, CR was twice as high for the aprepitant versus control regimen in the 6 months to\u00a0&lt;2 year group (50%\u00a0vs. 25%) and significantly higher in the 12\u201317 year group (40%\u00a0vs. 7%, <jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.05). CR was also significantly higher with aprepitant in the 6 months to\u00a0&lt;2 year and 12\u201317 year age groups who received VHEC. Similar proportions of subjects experiencing at least one adverse event were seen in both regimens across age categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A 3 day aprepitant regimen seemed effective and safe for prevention of chemotherapy\u2010induced nausea and vomiting in paediatric subjects across subgroups (ClinicalTrials.gov NCT01362530).<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.27273","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T12:11:40Z","timestamp":1528805500000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Aprepitant for the prevention of chemotherapy\u2010induced nausea and vomiting in paediatric subjects: An analysis by age group"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4671-0449","authenticated-orcid":false,"given":"Hyoung Jin","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Pediatrics Cancer Research Institute Seoul National University College of Medicine Seoul National University Children's Hospital  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Loftus","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"DiCristina","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-7135","authenticated-orcid":false,"given":"Stuart","family":"Green","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annpey","family":"Pong","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-9166","authenticated-orcid":false,"given":"Christian Michel","family":"Zwaan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology Erasmus MC\u2010Sophia Children's Hospital  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology: antiemesis (Version 2.2017).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed November 20 2017."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26542"},{"key":"e_1_2_9_5_1","unstructured":"Multinational Association of Supportive Care in Cancer.MASCC\/ESMO Antiemetic Guideline 2016 V.1.2.http:\/\/www.mascc.org\/assets\/Guidelines-Tools\/mascc_antiemetic_guidelines_english_2016_v.1.2.pdf. Accessed November 27 2017."},{"key":"e_1_2_9_6_1","unstructured":"Children's Oncology Group.Guidelines on chemotherapy\u2010induced nausea and vomiting in pediatric cancer patients.https:\/\/childrensoncologygroup.org\/downloads\/COG_SC_CINV_Guidelines_Document_July_2017.pdf. Accessed November 27 2017."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11433"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.050"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70061-6"},{"key":"e_1_2_9_11_1","volume-title":"EMEND (aprepitant) capsules for oral use, EMEND (aprepitant) for oral suspension [prescribing information]","year":"2015"},{"key":"e_1_2_9_12_1","unstructured":"National Cancer Institute.Common terminology criteria for adverse events v4.0 (CTCAE).https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed November 27 2017."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21811"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.27273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.27273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:43:23Z","timestamp":1694940203000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.27273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/pbc.27273"],"URL":"https:\/\/doi.org\/10.1002\/pbc.27273","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,12]]},"assertion":[{"value":"2017-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e27273"}}